Verastem (VSTM)
(Delayed Data from NSDQ)
$3.68 USD
-0.26 (-6.60%)
Updated Jun 4, 2024 04:00 PM ET
After-Market: $3.70 +0.02 (0.54%) 7:58 PM ET
3-Hold of 5 3
F Value F Growth A Momentum F VGM
Brokerage Reports
Verastem, Inc. [VSTM]
Reports for Purchase
Showing records 161 - 180 ( 264 total )
Company: Verastem, Inc.
Industry: Medical - Biomedical and Genetics
MID-DAY SUMMARY
Provider: Roth Capital Partners, Inc.
Company: Verastem, Inc.
Industry: Medical - Biomedical and Genetics
Company: Verastem, Inc.
Industry: Medical - Biomedical and Genetics
Clinical Programs On Track; Immunotherapy Results Expected in 2017; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: RAMAKANTH S
Company: Verastem, Inc.
Industry: Medical - Biomedical and Genetics
MORNING SUMMARY
Provider: Roth Capital Partners, Inc.
Company: Verastem, Inc.
Industry: Medical - Biomedical and Genetics
1Q16 Results; Looking for Programs to Ramp Up; Maintain Neutral
Provider: Roth Capital Partners, Inc.
Analyst: PANTGINIS J
Company: Verastem, Inc.
Industry: Medical - Biomedical and Genetics
Presentations at AACR Highlight Potential Future Developments; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: RAMAKANTH S
Company: Verastem, Inc.
Industry: Medical - Biomedical and Genetics
MORNING SUMMARY
Provider: Roth Capital Partners, Inc.
Company: Verastem, Inc.
Industry: Medical - Biomedical and Genetics
Second I-O Collaboration and Revamped Clinical Programs for 2016; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: RAMAKANTH S
Company: Verastem, Inc.
Industry: Medical - Biomedical and Genetics
2015 Results; Focusing on the Science Driven Drawing Board; Neutral
Provider: Roth Capital Partners, Inc.
Analyst: PANTGINIS J
Company: Verastem, Inc.
Industry: Medical - Biomedical and Genetics
Latest Data Continue to Support Combination Immunotherapy; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: RAMAKANTH S
Company: Verastem, Inc.
Industry: Medical - Biomedical and Genetics
MORNING SUMMARY
Provider: Roth Capital Partners, Inc.
Company: Verastem, Inc.
Industry: Medical - Biomedical and Genetics
A Path Forward Despite Losing COMMAND; Lowering PT to $5.00; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: RAMAKANTH S
Company: Verastem, Inc.
Industry: Medical - Biomedical and Genetics
Meso Wins; Stepping to Sidelines; Downgrade to Neutral; Target to $2
Provider: Roth Capital Partners, Inc.
Analyst: PANTGINIS J
Company: Verastem, Inc.
Industry: Medical - Biomedical and Genetics
Following Promising NSCLC Results, Focus Turns to COMMAND; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: RAMAKANTH S
Company: Verastem, Inc.
Industry: Medical - Biomedical and Genetics
After Abstract Debacle, ''6063 Data Impress in NSCLC
Provider: Roth Capital Partners, Inc.
Analyst: PANTGINIS J
Company: Verastem, Inc.
Industry: Medical - Biomedical and Genetics
MID-DAY SUMMARY
Provider: Roth Capital Partners, Inc.
Company: Verastem, Inc.
Industry: Medical - Biomedical and Genetics
MORNING SUMMARY
Provider: Roth Capital Partners, Inc.
Company: Verastem, Inc.
Industry: Medical - Biomedical and Genetics
Wait For NSCLC PhII Data at WCLC; Sell-Off Ignores Main Value Driver
Provider: Roth Capital Partners, Inc.
Analyst: PANTGINIS J
Company: Verastem, Inc.
Industry: Medical - Biomedical and Genetics
COMMAND''s First Hurdle Coming Up; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: RAMAKANTH S
Company: Verastem, Inc.
Industry: Medical - Biomedical and Genetics
2Q15 Results; Let''s See Where COMMAND Interim Leads Us
Provider: Roth Capital Partners, Inc.
Analyst: PANTGINIS J